DA-5222-R3
Phase 1Small molecule
DA-5222-R3 is one of 33 small molecule programs targeting Clinical Trial. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
136 competitors in Clinical Trial
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Avelox
BayerPhase 3
Paraplatin
AAvyxa
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 3
Potassium Iodide
MMeda Pharmaceuticals
Phase 3
Ablysinol
CSL BehringPhase 3
Nascobal
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
FOLFOXIRI
SSun Yat-sen University
Phase 3
JOINTSTEM
RR-Bio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DA-5222-R3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDong-A ST Co., Ltd.